Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Central Indiana – Indianapolis
    • Engage Northeast Indiana – Fort Wayne
    • Engage West Central Indiana – Terre Haute
    • Engage Greater Lafayette – West Lafayette
    • Engage Northwest Indiana – Valparaiso
    • Engage South Bend – Elkhart
    • Engage Southwest Indiana – Evansville
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Biopharma Company Hits Milestone for Indy Plant

Wednesday, April 28, 2021 05:39 PM EDT
By Alex Brown

Canada-based POINT Biopharma Inc. has cleared a key hurdle for its new production facility in Indianapolis. The U.S. Nuclear Regulatory Commission has issued a materials license for the radiopharmaceutical company’s facility, which authorizes the handling of nuclear material in chemical or physical form.

Last May, POINT Biopharma announced plans to invest $25 million to acquire and renovate a manufacturing center on the city’s northwest side and create more than 100 jobs. The company says it is finishing renovations at the facility and the NRC license will allow it to begin work with a variety of radioisotopes on-site.

“The completion of our Indianapolis facility and scope of this Materials License will enable POINT to quickly bring its drug manufacturing operations online,” said Todd Hockemeyer, executive vice president of U.S. manufacturing operations at POINT Biopharma. “Our mission is to make radioligand therapy applicable to more cancers, available to more people, thereby improving the lives of cancer patients and their families everywhere. This Materials License is an important milestone in our journey to deliver on our mission.”

The company will use the facility to produce and distribute 400,000 doses of its next generation cancer treatments known as radioligands. The company expects the Indy facility to begin providing treatments for its Phase 3 clinical trial targeting metastatic castration resistant prostate cancer later this year.

After the announcement of the facility was made last year, Chief Executive Officer Joe McCann appeared on Inside INdiana Business with Gerry Dick to talk about the project. You can watch the full interview in the video below:

 

Story Continues Below

Most Popular Stories

  • Graduation rates for Indiana schools could dip after state law change

  • State politicians talk rural housing challenges, stress local solutions

  • Fort Wayne Metals acquires tantalum equipment

  • Business growth: Explaining what you do

  • Buddy Guy, Clint Black among State Fair concert attractions

  • White Castle opens new Whiting location after historic building demolished

Perspectives

Business growth: Explaining what you do

Business growth: Explaining what you do

“We network networks.” In a bold stroke of bravado, Cisco Systems co-founder Sandy Lerner gave what is now known to be one of the most specific descriptions of her company that has ever been recorded. The statement, consisting of only three words, described EXACTLY what Cisco did as a company. And the rest is history....

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service